Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase II Trial of Adjuvant Cellular Immunotherapy for High-Risk Hematologic Malignancy After Reduced Intensity Allogeneic Stem Cell Transplantation

NCT00143845 is registered in ClinicalTrials.gov with University of Michigan Rogel Cancer Center as lead sponsor.

NCT NCT00143845
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00143845 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase II Trial of Adjuvant Cellular Immunotherapy for High-Risk Hematologic Malignancy After Reduced Intensity Allogeneic Stem Cell Transplantation
Lead sponsor
University of Michigan Rogel Cancer Center
Phase
Phase 2
Overall status
Completed
Start date
April 30, 2003
Completion date
February 28, 2013
Enrollment
54 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

lymphocytic leukemia, chronic, lymphoma, low-grade, multiple myeloma